Pomdoctor posted a 16.7% year-over-year revenue increase to US$57.2 million in fiscal year 2025, a result that on the surface validates the investment thesis around China's digital healthcare expansion. Net revenues reached RMB 399.9 million driven by a 69.3% surge in Internet hospital sales. But beneath this top-line strength lies a margin story that demands closer scrutiny.
The online pharmacy segment expanded 83.2% in the first half of 2025 alone, and this growth came at a cost. Gross margin contracted to 13.1% from 13.9% a year earlier-a 80-basis-point decline that accelerates a concerning trend. The CEO's commentary acknowledges the pressure: the company "deepened cooperation with pharmaceutical manufacturers to sell their products through its Internet hospital platform," which inherently means taking on more of the wholesale margin. When you sell more low-margin pharmacy products, the overall margin profile compresses.
What's telling is the cost trajectory. In the first half of 2025, revenue from online pharmacy sales increased from RMB 36.3 million to RMB 66.4 million-an 83% jump. Yet the cost of revenues in that segment more than doubled from RMB 51.0M to RMB 101.4M on a full-year basis. This isn't just margin compression; it's a structural cost shift that makes the 13% figure feel conservative rather than aspirational.
The market may be pricing in the revenue growth story while underestimating how far margins can erode as the company scales its pharmacy operations. A 9.6% gross profit increase trailing a 16.7% revenue increase is the mathematical signature of a business becoming less efficient at converting sales into profit. For investors, the question isn't whether growth is real-it is. The question is whether the profit trajectory can catch up, or whether Pomdoctor is trading margin for market share in a way that leaves it vulnerable when competition intensifies.
The Profitability Gap: Rising Losses and R&D Spike
The top-line growth story hits a wall when you look at what's happening to profitability. Pomdoctor's net loss exploded to RMB 130.9 million in fiscal 2025, up 250% from RMB 37.4 million a year earlier. That's the mathematical signature of a company spending aggressively to fuel expansion-and the CEO's commentary confirms this was deliberate.
The investment driving those losses is unmistakable. R&D expenses surged 328.5% year-over-year, a staggering increase that signals serious capital deployment into technology infrastructure and platform capabilities. The CEO framed these as "necessary and strategic investments" following the IPO, necessary costs that "enabled our transition to a publicly listed company" and "unlock[ed] broader growth opportunities." That's the company's framing-and it may well be correct from a strategic positioning standpoint. But the financial reality is that these investments are crushing near-term profitability.
What's concerning is the margin trajectory within the growth engine itself. The online pharmacy segment-the star performer with 83.2% growth in the first half of 2025-operates on razor-thin margins. The evidence shows revenue from online pharmacy sales jumped from RMB 36.3 million to RMB 66.4 million in H1 2025 alone, yet the cost of revenues in that segment more than doubled on a full-year basis. When you're moving products at 13% gross margin and the mix shifts heavily toward low-margin pharmacy sales, the profit conversion deteriorates rapidly.
The market may be pricing in the revenue growth and the IPO-related costs as one-time items. But the question is whether this loss expansion is transitional or structural. A 250% increase in net loss trailing a 16.7% revenue increase suggests the company is in a heavy investment phase-but it also means every yuan of revenue growth is being offset by multiple yuan in additional costs. For investors, the risk isn't that growth is fake. The risk is that the path to profitability keeps receding as the company scales, and the "growth at all costs" strategy leaves the stock vulnerable if capital markets tighten or competition intensifies.
Valuation and Investment Thesis: What's Priced In?
Pomdoctor's market positioning is respectable but not dominant-sixth in China's internet hospital market by contracted doctors is a solid foundation, yet it leaves the company exposed to more concentrated competitors. The real question for investors isn't about market rank; it's whether the current stock price reflects the profitability trajectory or simply bets on future margin recovery that may never arrive.
The numbers tell a concerning story. A 16.7% revenue increase trailing a 9.6% gross profit increase is the mathematical signature of margin compression-and the full-year gross margin of 13.1% represents an 80-basis-point decline from a year earlier. Net loss exploded to RMB 130.9 million, up 250% year-over-year. When losses expand faster than revenue, the business is becoming less, not more, efficient at converting sales into cash.
Here's where second-level thinking matters. The market may be pricing in the revenue growth story-the 16.7% top-line expansion, the 83.2% online pharmacy surge in H1 2025, the strategic R&D investments that surged 328.5%. These are real numbers, and they validate the company's expansion thesis. But the market may be underestimating how far margins can erode as the company scales its low-margin pharmacy operations. The CEO's commentary frames gross margin as "stable" at over 13%, yet the trajectory is unmistakably downward-and the H1 2025 figure of 16.2% gross margin that the CEO cited was for the six-month period, not the full year.
The asymmetry of risk is clear. On the upside, margin recovery would require either a meaningful shift in product mix away from low-margin pharmacy sales or operational improvements that outpace the cost inflation affecting the sector. On the downside, continued margin compression would mean every yuan of revenue growth is being offset by multiple yuan in additional costs-a structure that leaves the company vulnerable if capital markets tighten or competition intensifies.
For investors, the question isn't whether the growth is real. It is. The question is whether the current valuation discounts future margin recovery that may not materialize, or whether the market has already priced in the profitability risk. Given the 250% loss expansion and the structural shift toward low-margin pharmacy sales, the risk/reward ratio appears skewed. The market may be pricing for perfection-assuming margin stabilization that the operational reality doesn't yet support.
Catalysts and Risks to Watch
The next 12-18 months will determine whether Pomdoctor's revenue scale can finally convert into sustainable profits-or whether the company faces a liquidity crunch that forces a strategy reset. Four key variables will decide this binary outcome.
Gross margin trajectory is the primary catalyst. The company's FY2025 full-year gross margin of 13.1% represents an 80-basis-point decline year-over-year, yet the CEO described it as "stable" at over 13%. The CEO said the company maintained a steady gross margin over 13% while expanding pharmacy sales. For the investment thesis to recover, investors need to see pharmacy segment margins stabilize above 3%-a threshold that would signal the company has extracted sufficient scale to offset the low-margin product mix shift. FY2026 guidance will be critical: if margins continue drifting lower, the 16.7% revenue growth becomes a trap rather than a pathway to profitability.
R&D spend trajectory will test whether the 328.5% increase is investment or erosion. The company framed the surge as "necessary and strategic investments" following the IPO, focused on "enhancing technology-driven healthcare capabilities" and "strengthening platform infrastructure." R&D expenses surged 328.5% year-over-year-but the market needs to see tangible revenue products or efficiency gains emerging from this spend within the next two quarters. If the R&D outlay translates into new monetizable services (AI diagnostics, integrated insurance platforms, smart wearable ecosystems), the loss expansion becomes a temporary cost of entry. If not, it becomes a structural drag that compounds the margin problem.
Regulatory risk in China's digital health sector remains the wildcard. Pomdoctor operates in a space where policy shifts can rapidly alter unit economics. The company's deepening collaboration with pharmaceutical manufacturers and integration with online medical insurance systems across major cities accelerate the integration of our platform with online medical insurance systems-these are growth catalysts, but they also increase regulatory exposure. Any tightening of reimbursement rules or restrictions on cross-provincial online pharmacy sales could instantly invalidate the margin recovery thesis.
Cash position and burn rate create the liquidity timeline. With net loss of RMB 130.9 million in FY2025 and H1 2025 losses of RMB 19.9 million, the company is burning capital at an accelerating rate. The October 2025 IPO provided "additional capital resources," but the evidence doesn't specify the exact net proceeds or current cash balance. What matters is the runway: at current burn rates, how many quarters of operating losses can the company sustain before needing to raise additional capital or materially slow its expansion? The 250% loss expansion suggests the answer is "not many" if the trend continues.
The asymmetry here is stark. On the upside, margin recovery plus R&D monetization could unlock a compelling growth story in China's massive digital health market. On the downside, continued loss expansion without liquidity relief could force a painful strategic retreat. The market may be pricing for perfection-assuming the company will find the margin inflection point. Investors should watch the next two quarters closely: if gross margin doesn't stabilize and R&D doesn't show revenue traction, the risk/reward ratio deteriorates rapidly.